Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news: AMIC +20.8% (Co and Independence Holding (IHC) announced sale of stop loss business to Swiss Re Corporate Solutions for $152.5 mln in cash)
Select metals/mining stocks trading higher: HMY +7%, AEM +2.3%, AUY +2.1%, AU +1.9%, GFI +1.4%, NEM +1%, GG +0.9%, ABX +0.9%, SLW +0.8%
Other news: CNAT +23.7% (achieved positive results with Emricasan in initial stage of Phase 2 liver cirrhosis clinical trial), OXGN +7.1% (confirms the FDA granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors), MBLY +6.3% (signs Memorandum of Understanding with Volkswagen (VLKAY) and announces a strategic partnership to explore and integrate REM into Volkswagen's fleet), VICL +5.2% ( confirms the FDA granted Orphan Drug Designation for VL-2397 for the treatment of invasive aspergillosis), KANG +4.5% (cont strength), HLTH +2.5% (intended to restate consolidated financial statements for FY14 and for 2015 interim periods), WATT +1.4% (introduced the first miniature WattUp transmitter design that is both small and cost effective enough to ship in-box with small wearable and IoT devices.)
Analyst comments: TASR +3.2% (upgraded to Overweight from Neutral at JP Morgan)
In reaction to strong earnings/guidance: N/A.
M&A news: AMIC +20.8% (Co and Independence Holding (IHC) announced sale of stop loss business to Swiss Re Corporate Solutions for $152.5 mln in cash)
Select metals/mining stocks trading higher: HMY +7%, AEM +2.3%, AUY +2.1%, AU +1.9%, GFI +1.4%, NEM +1%, GG +0.9%, ABX +0.9%, SLW +0.8%
Other news: CNAT +23.7% (achieved positive results with Emricasan in initial stage of Phase 2 liver cirrhosis clinical trial), OXGN +7.1% (confirms the FDA granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors), MBLY +6.3% (signs Memorandum of Understanding with Volkswagen (VLKAY) and announces a strategic partnership to explore and integrate REM into Volkswagen's fleet), VICL +5.2% ( confirms the FDA granted Orphan Drug Designation for VL-2397 for the treatment of invasive aspergillosis), KANG +4.5% (cont strength), HLTH +2.5% (intended to restate consolidated financial statements for FY14 and for 2015 interim periods), WATT +1.4% (introduced the first miniature WattUp transmitter design that is both small and cost effective enough to ship in-box with small wearable and IoT devices.)
Analyst comments: TASR +3.2% (upgraded to Overweight from Neutral at JP Morgan)